Evolus Inc
evolus.comWhat Do They Do?
Sells Jeuveau and injectable hyaluronic acid gels to licensed aesthetic practitioners.
10-K for FY2025, filed Mar 3, 2026We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the…View ↗
Our current commercially available products and our product candidates represent two of the largest product categories within medical…View ↗
Jeuveau® is a proprietary 900 kilodalton (“kDa”), purified botulinum toxin type A formulation indicated for the temporary improvement in…View ↗
Evolysse™ is a collection of injectable HA gels that utilizes first-generation cold technology. The line includes a variety of products…View ↗
How Do They Make Money?
The company sells Jeuveau and Evolysse products to practitioners; customers pay within a year of receiving them. In Canada, it earns service revenue from Jeuveau distribution through a partner, as the service is performed.
10-K for FY2025, filed Mar 3, 2026For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an…View ↗
A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts…View ↗
Net revenues increased by $30.9 million, or 11.6%, to $297.2 million for the year ended December 31, 2025 from $266.3 million for the year…View ↗
For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent…View ↗
-
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by product or service ↗
$297.2M
-
10-K for FY2025, filed Mar 3, 2026
$297.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 3, 2026 |
99%
FY2022: 99%
|
Product revenue, net, FY2025
$295M Sources
|
Sold outright |
|
Service revenue
|
0.8%
FY2022: 1.4%
|
Service revenue, FY2025
$2.2M Sources
|
Who Are Their Customers?
Licensed aesthetic practitioners are the customers; Jeuveau sales in Canada go through a distribution partner.
10-K for FY2025, filed Mar 3, 2026
Do Revenues Turn Into Profits?
No. It lost $51.6M in FY2025.
10-K for FY2025, filed Mar 3, 2026
−$32.7MView ↗
10-K for FY2025, filed Mar 3, 2026
−$51.6MView ↗
10-K for FY2025, filed Mar 3, 2026
−$45.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$8.1MView ↗
- ▼ −53% (Loss)
- vs −$17.1M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 5, 2026
Open tableView ↗
-
Aug 5, 2026
Raises full-year revenue guidance
Raised the 2026 net revenue outlook to between $330 million and $337 million.
Sources
8-K, filed Aug 5, 2026
Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market…View ↗
-
Aug 4, 2026
Adds Estyme commercialization rights in Canada, Australia and New Zealand
The amendment grants exclusive rights to commercialize the full Estyme line in those territories.
Sources
8-K, filed Aug 4, 2026
The Amendment expands the territory covered by the Agreement to include (i) Canada and (ii) Australia and New Zealand combined, and grants…View ↗
-
Jul 8, 2026
Licenses U.S. development and commercialization rights for Profhilo
Evolus will handle U.S. development and regulatory work, then commercialize the product if approved.
Sources
8-K, filed Jul 8, 2026
On July 7, 2026, Evolus, Inc. (the “Company”) and IBSA Institut Biochimique SA (“IBSA”) entered into a License, Supply and Distribution…View ↗
Growing. Revenue grew 3.0x in 4 years, from $99.7M in FY2021 to $297.2M in FY2025, about 31% a year.
Added hyaluronic acid gels
The portfolio expanded beyond Jeuveau to include Evolysse injectable hyaluronic acid gels.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 3, 2026Our first commercial product is Jeuveau®, which is a proprietary 900 kilodalton, or kDa, purified botulinum toxin type A formulation…View ↗
We are a global performance beauty company delivering breakthrough products with a customer-centric approach in the cash-pay aesthetic…View ↗
Who Do They Compete With?
Competes with Abbvie, Galderma, Merz, Revance, Hugel, Prollenium Medical Technologies, Obagi, Sanofi, Sun Pharma, Johnson & Johnson, and L’Oreal
10-K for FY2025, filed Mar 3, 2026There are only six approved injectable botulinum toxin type A neurotoxins in the United States for aesthetic indications, including…View ↗
Loading...
